XOMA Earns $25 Million Milestone Payment as Anti-TGF? Antibody Enters Phase 2 Clinical Study in Metastatic Pancreatic Cancer

Stock Information for XOMA Royalty Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About XOMA Royalty Corporation

XOMA Royalty Completes Sale of Kinnate Pipeline Assets
XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference
XOMA Royalty Declares Quarterly Preferred Stock Dividends
XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements
XOMA Royalty to Present at Investor Conferences in March
XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
XOMA Royalty Declares Quarterly Preferred Stock Dividends
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.